Xueying Li

Dr. Xueying Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2022 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
XLXueying Li
Xueying Li
JLJinli Lin
Jinli Lin
LZLinhao Zhang
Linhao Zhang
YLYao Liu
Yao Liu

20 May 2024 in Gynecologic and Obstetric Investigation
Verified
Journal Article
Closed access
PDF file
RCRui Cai
Rui Cai
JLJinli Lin
Jinli Lin
YLYao Liu
Yao Liu
LZLinhao Zhang
Linhao Zhang
XLXueying Li
Xueying Li
Introduction: Phloroglucinol may be able to improve embryo transfer outcomes. We aimed to systematically evaluate the effects of phloroglucinol on embryo transfer outcomes. Methods: The databases searched were PubMed, Ovid MEDLINE, Web of Science, Wanfang, CQVIP, China National Knowledge Infrastructure, and ClinicalTrials.gov. The last search was on February 7, 2023. The included studies were written in English or Chinese. Randomized controlled trials and cohort studies aiming to assess the effect of phloroglucinol on embryo transfer outcomes were included. The studies reported at least one of the primary outcomes (biochemical pregnancy rate, clinical pregnancy rate, and live birth rate). The odds ratio (OR) and 95% confidence interval (CI) were calculated. A random-effects or fixed model was used where applicable to estimate the results. Results: Seventeen articles reporting 5,953 cycles were included. Biochemical pregnancy rate (OR = 1.58, 95% CI = 1.20–2.08, I2 = 71%), clinical pregnancy rate (OR = 1.69, 95% CI = 1.35–2.10, I2 = 64%), and live birth rate (OR = 1.45, 95% CI = 1.23–1.71, I2 = 36%) were improved by phloroglucinol. Less miscarriage (OR = 0.46, 95% CI = 0.35–0.60, I2 = 0%), less ectopic pregnancy (OR = 0.45, 95% CI = 0.28–0.72, I2 = 0%), higher implantation rate (OR = 1.45, 95% CI = 1.24–1.71, I2 = 62%) but more multiple pregnancy rate (OR = 1.48, 95% CI = 1.13–1.94, I2 = 0%) were induced by phloroglucinol. Endometrial peristaltic waves were improved by phloroglucinol (OR = 22.87, 95% CI = 5.52–94.74, I2 = 72%). Conclusion: Phloroglucinol may improve the outcomes of embryo transfer, including biochemical pregnancy, clinical pregnancy, and live birth rates. Further studies are warranted.

17 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LZLinhao Zhang
Linhao Zhang
JLJinli Lin
Jinli Lin
XLXueying Li
Xueying Li
Background/Objectives: Helicobacter pylori (H. pylori) positivity is associated with peptic ulcers in the general population. However, its role in peptic ulcers in cirrhotic patients remains controversial. The impact of H. pylori infection status on the treatment outcomes of peptic ulcers in liver cirrhosis was investigated. Methods: A systematic review and network meta-analysis was performed. The following databases were searched: Ovid MEDLINE, PubMed, Web of Science, CQVIP, Wanfang, China National Knowledge Infrastructure, chictr.org.cn, and ClinicalTrials.gov. Relevant studies were published up to 31 December 2025. Studies comparing the treatment outcomes of peptic ulcers in liver cirrhosis were included. Patients were divided into three groups: Hp_pos group (including those who failed to eradicate H. pylori and who denied eradication therapy), Hp_neg group (H. pylori-uninfected individuals), and Hp_Erad group (H. pylori tested positive at baseline but was successfully eradicated afterwards). Prospero registration number: CRD42024551260. Results: Four prospective studies were eligible. No significant difference was found in the unhealed peptic ulcers or recurrent peptic ulcers, although the Hp_Erad group had the highest values of the surface under the cumulative ranking curve (SUCRA) [(0.773, mean rank: 1.5) and (0.809, mean rank: 1.4), respectively]. Conclusions: Based on the available low-quality evidence, this network meta-analysis did not detect a statistically significant benefit of H. pylori eradication for ulcer healing or recurrence prevention in cirrhotic patients. These findings should be interpreted as highlighting an evidence gap rather than providing definitive evidence. Further randomized controlled trials are necessary to confirm these findings. Clinical decisions regarding H. pylori eradication in cirrhotic patients should be made carefully, weighing the potential benefits against the risks.